Overview

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Status:
Withdrawn

Trial end date:
2019-04-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with epithelial ovarian cancer who have progressed on or after SoC therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

ImmunityBio, Inc.
NantCell, Inc.

Treatments:

Avelumab
Bevacizumab
Capecitabine
Cyclophosphamide
Fluorouracil
Fulvestrant
Leucovorin
Oxaliplatin
Paclitaxel
Vaccines